
Genome Biologics is a biotechnology company specializing in therapeutic target and drug discovery for cardiovascular and cardiometabolic diseases. Their business model focuses on developing transformative RNA-targeted therapies, leveraging AI-driven big data analytics integrated with precision preclinical organoid and in vivo disease models for therapeutic validation. Their technology platforms, GENIMAPS® and GENISYST®, enable accelerated drug discovery and stringent efficacy validation through seamless translation of AI analytics into ex vivo and in vivo models. The company has a rich therapy pipeline targeting cardiotoxicity, heart failure, and hypertrophic cardiomyopathy, employing strategies like cellular metabolic modulation and cardiac regeneration reactivation. Genome Biologics is a resident company at Johnson & Johnson Innovation - JLABS and has received European Union H2020 SME Instrument Phase 1 and 2 awards, reflecting strong traction and recognition in the biotech innovation ecosystem.

Genome Biologics is a biotechnology company specializing in therapeutic target and drug discovery for cardiovascular and cardiometabolic diseases. Their business model focuses on developing transformative RNA-targeted therapies, leveraging AI-driven big data analytics integrated with precision preclinical organoid and in vivo disease models for therapeutic validation. Their technology platforms, GENIMAPS® and GENISYST®, enable accelerated drug discovery and stringent efficacy validation through seamless translation of AI analytics into ex vivo and in vivo models. The company has a rich therapy pipeline targeting cardiotoxicity, heart failure, and hypertrophic cardiomyopathy, employing strategies like cellular metabolic modulation and cardiac regeneration reactivation. Genome Biologics is a resident company at Johnson & Johnson Innovation - JLABS and has received European Union H2020 SME Instrument Phase 1 and 2 awards, reflecting strong traction and recognition in the biotech innovation ecosystem.
Founded: 2016
Headquarters: Frankfurt, Germany
Focus: RNA-targeted therapies & human cardiac organoid platforms for cardiovascular/cardiometabolic disease
Key platforms: TrueCardium®, GENIMAPS®, GENISYST®
Notable support: European Innovation Council grants and JLABS residency
Therapeutic target discovery and drug development for cardiovascular and cardiometabolic disease, including cardiotoxicity and heart failure.
2016
Biotechnology
€2.4M
May 2018 EIC grant recorded in Dealroom
H2020 SME Instrument Phase 1 and 2 awards noted
14189032
Last funding date listed in company snapshot data
“Non-dilutive EU program funding (European Innovation Council / EIC, EASME) and incubator residency at Johnson & Johnson Innovation - JLABS”